Affiliation:
1. Baotou Central Hospital
2. Tongji University School of Medicine
3. Affiliated Hospital of Inner Mongolia Medical University
4. The first affiliated Hospital, Baotou medical college
5. Huashan Hospital Affiliated to Fudan University
Abstract
Abstract
Background Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that plays a critical role in the development and progression of tumors. Recent studies have assessed the relationship between expression level of hypoxia-inducible factor 1α (HIF1A) and prognosis in gliomas patients, and some of the results indicated the gliomas patient with high expression level of HIF1A seemed to have relatively poor prognosis. However, the heterogeneity among these studies was large. So to comprehensively and quantitatively summarize the evidence on the survival of patients with gliomas, a meta-analysis and a bioinformatics analysis was performed.Results Totally, 12 papers including 912 patients were subjected to final analysis. The combined hazard ratio (HR) was 1.47 (95% CI: 1.24–1.70) in the analyses of OS, and the significant heterogeneity (I2 = 48.0%, P = 0.027) was observed. Further, subgroup analyses by ethnicity were conducted: the combined hazard ratio (HR) for Caucasian was 1.30 (95% CI: 1.03 − 1.56, I2 = 40.1%, p = 0.112), and that for Asian was 2.03 (95% CI: 1.56–2.50, I2 = 9.0%, p = 0.355). By analyzing the datasets from The Cancer Genome Atlas (TCGA), The Genotype-Tissue Expression (GTEx) ,Chinese Glioma Genome Atlas (CGGA) and cBioPortal for Cancer Genomics, it was found that there were significantly different for HIF1A expressional levels between gliomas and the normal samples, and HIF1A expressional levels were related to overall survival rate (OS), tumor recurrence and some prognostic factors (eg. 1p/19q co-deletion, IDH mutation and MGMT methylation) of giloma patients.Conclusions Taken together, HIF1A could be a diagnostic marker and independent prognostic factor for gliomas, and comparing with Caucasian patients, Asian patients with HIF1A overexpression tended to have a more poor prognosis.
Publisher
Research Square Platform LLC
Reference46 articles.
1. Ghiaseddin AP, Shin D, Melnick K., et al. Tumor Treating Fields in the Management of Patients with Malignant Gliomas. Curr Treat Options Oncol. 2020 Jul 30;21(9):76.
2. Correlation of hypoxia as measured by fluorine-18 fluoroerythronitroimidazole (18F-FETNIM) PET/CT and overall survival in glioma patients;Hu M;Eur J Nucl Med Mol Imaging
3. Qiu GZ, Liu Q, Wang XG., et al. Hypoxia-induced USP22-BMI1 axis promotes the stemness and malignancy of glioma stem cells via regulation of HIF-1α. Life Sci 2020 Apr 15;247:117438.
4. Current status and recent advances in reirradiation of glioblastoma;Minniti G;Radiat Oncol
5. Liu H, Chen C, Zeng J., et al. MicroRNA-210-3p is transcriptionally upregulated by hypoxia induction and thus promoting EMT and chemoresistance in glioma cells. PLoS One. 2021 Jul 1;16(7):e0253522.